A Multicenter, Open-label, Clinical Pharmacology Trial to Determine the Pharmacokinetics, Tolerability, and Safety of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Latest Information Update: 05 May 2022
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 20 Apr 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 18 Nov 2021 New trial record